Figure 7.

Administration of XF-MSCs increases the protective effects against dextran sulfate sodium (DSS)-induced colitis in mice. (A) Schematic presentation of experimental design. (B) The percentage of body weight loss and (C) the survival rate of mice were measured until day 11. On day 7, (D) disease activity index for colitis severity was measured as clinical progression. Mice were sacrificed 11 days after induction of colitis with 3% DSS, and (E,G) the colon length, (F) weight-to-length ratios of the colons were measured. n = 7~10 mice per group. (H) Colon sections were stained with H&E and (I) histopathologic evaluation was carried out by determining lymphocyte inflammation and crypt damage degrees. (−): negative control group, (+): DSS-administered group, FBS: WJ-MSCs cultured in FBS conditions, XF: WJ-MSCs cultured in XF conditions. (* p < 0.05, ** p < 0.01).